PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the ...

Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...

The "Fill Finish Manufacturing Market - A Global and Regional Analysis: Focus on Product, End Users, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance ...

The MarketWatch News Department was not involved in the creation of this content. Proven leaders in biologics manufacturing are aligning their strengths to deliver a more efficient and cost-optimized ...

A straZeneca plans to invest $50 billion in its medicine manufacturing and R&D operations across the United States by 2030. The investment is expected to create tens of thousands of new, highly ...

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...